1. Plectin-1-targeted recognition for enhancing comprehensive therapy in pancreatic ductal adenocarcinoma.
- Author
-
Zhu Q, Zeng S, Yang J, Zhuo J, Wang P, Wen S, and Fang C
- Subjects
- Humans, Cell Line, Tumor, Animals, Mice, Nanoparticles chemistry, Nanoparticles therapeutic use, Apoptosis drug effects, Indocyanine Green chemistry, Indocyanine Green pharmacokinetics, Photothermal Therapy, Mice, Nude, Plectin metabolism, Plectin chemistry, Carcinoma, Pancreatic Ductal therapy, Carcinoma, Pancreatic Ductal pathology, Carcinoma, Pancreatic Ductal drug therapy, Deoxycytidine analogs & derivatives, Deoxycytidine chemistry, Deoxycytidine pharmacology, Deoxycytidine therapeutic use, Gemcitabine, Pancreatic Neoplasms pathology, Pancreatic Neoplasms therapy, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms metabolism
- Abstract
Pancreatic ductal adenocarcinoma (PDAC) poses a formidable challenge due to its aggressive nature and poor prognosis. Gemcitabine (Gem), a primary therapeutic option, functions by inhibiting DNA synthesis and promoting apoptosis, thereby impeding the progression of PDAC. However, Gem is hindered by suboptimal pharmacokinetics and efficacy. In response to these challenges, we have developed a nanoparticle (NP) designed for specific recognition of plectin-1 in PDAC cell membranes. The NPs encapsulate Gem while demonstrating pH-responsive drug release characteristics in the acidic tumor microenvironment. This targeted approach enhances local drug delivery while alleviating concerns about systemic toxicity. Furthermore, the NPs are enriched with indocyanine green (ICG), renowned for its strong photothermal effects, thereby further enhancing therapeutic outcomes. This study presents an innovative therapeutic strategy for PDAC based on a plectin-1-targeted recognition delivery approach. The approach is applied to enhance chemotherapy, combined with photothermal therapy (PTT), inducing apoptosis in PDAC cell lines and improving the pharmacokinetics of Gem. In conclusion, the delivery strategy based on plectin-1-targeted recognition shows promising preclinical prospects for enhancing therapeutic efficacy in PDAC, offering valuable insights for future clinical applications.
- Published
- 2024
- Full Text
- View/download PDF